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doi:10.1016/j.jmii.2011.04.002Background: Immediate removal of central venous catheters (CVCs) is not possible in patients
with candidemia requiring total parenteral nutrition (TPN). This study analyzed the possible
prognostic factors for survival time after onset of candidemia among nonneutropenic adults
requiring TPN.
Methods: We conducted a retrospective analysis from September 2003 to August 2005.
Results: A total of 59 nonneutropenic adults with candidemia and requiring TPN were identi-
fied retrospectively. All Candida isolates were susceptible to flucytosine and amphotericin
B. With the exception of one C glabrata isolate, all other isolates were susceptible to flucona-
zole and itraconazole. The only predictor of 30-day survival rate after onset of candidemia
identified in our analysis was an Acute Physiology and Chronic Health Evaluation II (APACHE
II) score of 23 points or less. Adults with higher APACHE II scores, who did not have their CVCs
changed, did not receive antifungal treatment, or who had thrombocytopenia had shorter
survival times after the onset of candidemia.
Conclusions: APACHE II scores, thrombocytopenia, antifungal agents, and CVCs changes are
associated with survival time in nonneutropenic adults requiring TPN after the onset of candi-
demia.
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The frequency of Candida bloodstream infections has
increased in recent decades. The risk factors for candide-
mia have been well documented and include total paren-
teral nutrition (TPN).1e3 Several reports have revealed that
the earlier a central venous catheter (CVC) is removed, the
better the response is to antifungal therapy.4,5 Retention of
CVCs was shown to be a significant risk factor and was
associated with higher mortality in patients with candide-
mia.4,5 However, immediate removal of CVCs is not possible
in patients requiring TPN after the onset of candidemia. We
conducted a retrospective study to analyze the possible
prognostic factors after the onset of candidemia among
nonneutropenic adults requiring TPN.
Methods
Study population
A retrospective cohort study was performed from
September 2003 to August 2005 at a 2,900-bed tertiary
referral medical center where there were specialized units
for bone marrow and solid organ transplantation, cardiac
monitoring, burn care, and intensive care. We reviewed the
medical records of adults who required TPN for nutritional
support because they were not able to feed enterally.
Among these patients, those who developed candidemia
during administration of TPN were included in this study.
Those patients with less than 500 cells/mm3 of absolute
neutrophil count at the onset of candidemia were
excluded. If the patients could resume feeding enterally
and their TPN could be discontinued within 1 week after the
onset of candidemia, they were excluded. Information,
including demographic characteristics, medical history,
invasive procedures, medications, laboratory data, and
outcome, were collected for analysis.
Definition of terms
Candidemia was defined as the presence of at least one
blood culture yielding Candida species. Nosocomial candi-
demia was defined as symptoms associated with candide-
mia occurring 48 hours or more after admission. Chronic
respiratory failure was defined by the presence of chronic
obstructive pulmonary disease or chronic restrictive
pulmonary disease diagnosed on the basis of history, phys-
ical examination, chest radiography, and respiratory func-
tion tests. Thrombocytopenia was defined as a platelet
number below 150,000 cells/mL of blood. Recent intra-
abdominal surgery was defined as intra-abdominal surgery
performed within 1 month before onset of candidemia.
Recent chemotherapy was defined as chemotherapy
administered within 1 month before onset of candidemia.
Chronic steroid treatment was defined as use of a dose
equivalent to at least 20 mg prednisolone per day for more
than 7 days within 1 month of the onset of candidemia.6
Congestive heart failure was diagnosed by a cardiovas-
cular physician according to the Framingham Heart Study
criteria.7 Shock was defined as a decrease in systolic bloodpressure to less than 90 mmHg or a decrease of at least
40 mmHg below baseline blood pressure despite adequate
fluid resuscitation. According to the Sepsis-related Organ
Failure Score criteria, the diagnosis of acute respiratory
failure was based on the ratio of arterial oxygen tension to
fractional inspired oxygen of lower than 200 mmHg.8 Acute
renal failure was defined according the Risk, Injury, Failure,
Loss, End stage classification of acute renal failure pub-
lished by the Acute Dialysis Quality Initiative group in
2004.9 Severity of illness was assessed using the Acute
Physiology and Chronic Health Evaluation II (APACHE II)
within 72 hours after the symptoms associated with candi-
demia occurred.10 Acid-suppressant therapy was defined as
the use of proton pump inhibitors or H2 blockers for more
than 7 days within 1 month before the onset of candidemia.
Species identification and antifungal susceptibility
testing
Blood samples were processed using a BACTEC NR-660
system (Becton Dickinson Diagnostic Instrument Systems,
Spark, MD, USA). Organisms were initially identified by via
germ tube analysis and colony morphology on brain heart
infusion agar. If necessary, they were also assessed by
standard biochemical testing using an ATB ID 32C system
(bioMe´rieux, Marcy-l’Etoile, France) and Yeast Biochemical
Cards (Vitek; bioMe´rieux, Marcy-l’Etoile, France).
Susceptibility of the isolates was evaluated for four
antifungal agents, including flucytosine, itraconazole, flu-
conazole, and amphtericin B, using an ATB fungus 2 test
(bioMe´rieux SA, Marcy-l’Etoile, France) according to the
manufacturer’s instructions. The cutoff point of minimal
inhibitory concentration (MIC) for flucytosine, itraconazole,
fluconazole, and amphotericin B was less than 4 mg/L, less
than 0.125 mg/L, less than 8 mg/L, and less than 2 mg/L,
respectively.11,12
Statistical analysis
Univariate analyses were used to identify the factors
associated with 30-day survival rate. Pearson’s c2 test or
Fisher’s exact two-tailed test was used to examine nominal
data, and an unpaired Student t test was used for contin-
uous data. A value of p less than 0.05 was considered
statistically significant. The independent factors for 30-day
survival were identified by stepwise logistic regression of
multivariate analysis. The survival time after onset of
candidemia was compared by Kaplan-Meier survival
methods. Possible confounding factors were checked by
Cox regression models. SPSS 11.5 software for MS Windows
(SPSS Inc., Chicago, IL, USA) was used for statistical
analysis.
Results
Candidemia occurred in a total of 59 nonneutropenic adults
requiring TPN from September 2003 to August 2005. Forty
patients were males and the mean age was 66 years with
a range of 23e89 years. All episodes of candidemia were
nosocomial, and the time of infection was 3e126 days
(median 38 29.9 days) after admission. The mean
Candidemia in patients requiring TPN 463duration of hospitalization was 73 50.5 days. The mean
duration of antibiotic use before occurrence of symptoms
related to candidemia was 28 24.4 days. Nearly all
patients had tachycardia (100.0%) and fever (98.3%). Severe
complications, such as shock (44.1%), acute renal failure
(33.9%), and thrombocytopenia (55.9%), were common, and
the mean APACHE II score was 22 7.1 points. Thirty-eight
isolates were identified as C albicans, 9 were C para-
psilosis, 7 were C glabrata, and 5 were C tropicalis. All
Candida isolates were susceptible to flucytosine and
amphotericin B. With the exception of one C glabrata
isolate, all the other isolates were susceptible to flucona-
zole and itraconazole.
The overall 30-day survival rate was 45.8% (27/59) after
the onset of candidemia. There were six patients who did
not receive antifungal treatment and 53 patients who did
receive antifungal treatment after the onset of candide-
mia. The median number of days from the onset of candi-
demia to administration of antifungal agents was 3 (range
9e22 days). There were six patients with breakthrough
candidemia and all of these patients received fluconazole
before the onset of candidemia. The mean cumulative dose
of fluconazole among these patients was 2,000 mg (range
800e3,600 mg). Three of these patients continued fluco-
nazole treatment because of susceptibility, and they all
died within 30 days after the onset of candidemia.
Amphotericin B replaced the use of fluconazole in the other
three patients, and one of these patients survived more
than 30 days. There were 43 patients who initially received
fluconazole treatment after the onset of candidemia. Flu-
conazole was continued in 33 of these patients and was
shifted to amphotericin B in the other 10 patients. Among
the former, 17 of 33 patients survived more than 30 days,
and among the latter, 7 of 10 patients survived more than
30 days. Among the patients initially receiving amphoter-
icin B, two of four survived more than 30 days. No specific
antifungal regimen was more effective than the others.
There were 50 patients who received a change in their
CVC and 9 patients who did not receive a change in their
CVC after the onset of candidemia. Among the latter, all
died within 30 days after onset of candidemia. Among the
former, the median number of days from the onset of
candidemia to the change in CVC was 2 days (range 0e22
days). Sixteen of 32 patients whose CVCs were changed
within 3 days after the onset of candidemia survived more
than 30 days. Eleven of 18 patients whose CVCs were
changed more than 3 days after the onset of candidemia
survived more than 30 days. There was no statistically
significant difference for 30-day survival rates between
these two groups (16/32 vs. 11/18; pZ 0.645).
To assess the risk factors associated with 30-day
survival, univariate analysis was performed and the result is
presented in Table 1. Recent chemotherapy, an APACHE
score of 23 points or higher, absence of antifungal therapy,
and not changing CVCs were demonstrated to be associated
with 30-day survival. After multivariate logistic regression,
the only independent factor for 30-day survival was an
APACHE II score of 23 points or higher (odds ratio 4.643; 95%
confidence interval 1.355e15.908; pZ 0.009).
Survival times after the onset of candidemia were
compared by Kaplan-Meier survival methods. In the univar-
iate analysis of 30-day survival, the factors with a p valueless than 0.5 were considered as probable confounding
factors for survival time after onset of candidemia and were
included in multivariate Cox regression models. The non-
neutropenic adults requiring TPN with higher APACHE II
scores, no change of their CVCs, absence of antifungal
therapy, or thrombocytopenia demonstrated shorter
survival times after the onset of candidemia (Table 2).Discussion
CVCs have extensive clinical application in intensive care
but are often related to infectious complications. Several
reports revealed that the earlier CVCs are removed, the
better the response is to antifungal therapy.4,5 In addition,
candidemia was prolonged by a median of 3 days when CVCs
were not removed immediately in neonates.5 Candida was
shown to produce biofilms in high-glucose medium and
colonize indwelling CVCs.13 The large size of Candida
hyphae and pseudohyphae may preclude macrophages from
phagocytosis and invasion of vascular structures, facili-
tating dissemination of Candida.14 When the catheters are
retained, it is difficult to eradicate intravenous Candida.
Immediate removal of CVCs has been advised in clinical
practice guidelines for the management of candidiasis, but
it is impossible in some patients, such as patients requiring
TPN.15
In this study, all the patients who did not have their CVCs
changed died within 28 days. The patients whose CVCs were
changed had a longer survival time. Changing of CVCs could
decrease biofilm formation and then subsequently increase
the efficacy of antifungal agents. However, the correct
time to change CVCs is unknown for these patients. In our
study, change of CVCs within 3 days after the onset of
candidemia did not demonstrate a beneficial effect on 30-
day survival rates. Recolonization of Candida species in new
CVCs is a problem when intravenous Candida are not
eradicated by antifungal agents in those patients whose
CVCs were changed immediately after onset of candidemia.
Temporary use of peripheral parenteral nutrition to replace
TPN may be more suitable for the treatment of candidemia
in these patients. However, peripheral lines are difficult to
assess in some patients and changing CVCs is very risky in
patients with bleeding tendencies. An in vitro study has
shown that doxycyline-based antifungal agents are effec-
tive for the treatment of C albicans biofilms.16 Liposomal
amphotericin B and amphotericin B lipid complex all have
been shown to be effective against Candida biofilms
in vitro,17,18 and caspofungin was demonstrated to be
effective for the treatment and prevention of C albicans
biofilms in mice.19 Although there have been no clinical
studies in humans, these new antifungal agents might be
considered in patients with candidemia whose CVCs cannot
be removed or changed.
The APACHE II score is the most important prognostic
factor associated with survival rate in patients with can-
didemia.3,20e23 In our study, APACHE II scores were related
to survival time and 30-day survival rates in patients
requiring TPN. Among our patients, several had break-
through infections. Although clinical isolates were suscep-
tible to fluconazole in vitro, continuous use of fluconazole
was not effective for the treatment of this kind of
Table 1 Characteristics associated with 30-day survival after onset of candidemia according to univariate analysis among
patients requiring TPN
Variable Survival (nZ 27) Death (nZ 32) p
Age 65 yr or older 17 (63.0) 22 (68.8) 0.848
Gender, male 17 (63.0) 23 (71.9) 0.653
Candida albicans 17 (63.0) 21 (65.6) 1.000
Onset of candidemia in the intensive care unit 15 (55.6) 14 (43.8) 0.521
Underlying disease
Recent intra-abdominal surgery 17 (63.0) 18 (56.3) 0.797
Ventilator support 9 (33.3) 14 (43.8) 0.583
Recent chemotherapy 0 (0.0) 7 (21.9) 0.012*
Chronic steroid therapy 5 (18.5) 8 (25.0) 0.777
Chronic respiratory failure 5 (18.5) 7 (21.9) 1.000
Congestive heart failure 3 (11.1) 2 (6.3) 0.652
Diabetes mellitus 4 (14.8) 4 (12.5) 1.000
Acid suppressant therapy 16 (59.3) 25 (78.1) 0.199
End-stage renal disease 2 (7.4) 1 (3.1) 0.593
Signs
Shock 10 (37.0) 16 (50.0) 0.462
Acute renal failure 7 (25.9) 13 (40.6) 0.362
Conscious change 4 (14.8) 11 (34.4) 0.156
Thrombocytopenia 12 (44.4) 21 (65.6) 0.171
APACHE score of 23 points or higher 7 (25.9) 20 (62.5) 0.011*
Therapy
No use of antifungal therapy 0 (0.0) 6 (18.8) 0.027*
No change of CVCs 0 (0.0) 9 (28.1) 0.003*
Fluconazole therapy 25/27 (92.6) 24/26 (92.3) 1.000
Antifungal therapy was started within 3 d after onset of candidemia 21/27 (77.8) 19/26 (73.1) 0.938
Change of CVCs within 3 d after onset of candidemia 16/27 (59.3) 16/23 (69.6) 0.645
APACHEZ Acute Physiology and Chronic Health Evaluation; CVCsZ central venous catheters; SDZ standard deviation; TPNZ total
parenteral nutrition.
Data are presented as n (%) or mean SD.
*p< 0.05.
464 C.-C. Tsai et al.candidemia. One study showed that the MICs of Candida
isolates to fluconazole correlated with daily and cumulative
doses of fluconazole in the patients with breakthrough
infections,24 and the patients with a higher cumulative doseTable 2 Hazard ratios of all probable confounding factors for
requiring TPN by multivariate Cox regression models
Probable variables Hazard ratio
APACHE II score of 23 points or higher 2.793
No change of central venous catheters 9.013
No use of antifungal therapy 33.509
Thrombocytopenia 2.988
Shock 1.691
Acute renal failure 1.502
Conscious change 1.142
Age 65 yr or older 0.663
Acid-suppressant therapy 1.480
Recent chemotherapy 0.745
APACHEZ Acute Physiology and Chronic Health Evaluation; TPNZ to
*p< 0.05.of fluconazole were more likely to be infected with isolates
of Candida with higher MICs to fluconazole. In addition to
fluconazole, breakthrough candidemia can also occur with
amphotericin B and caspofungin.25,26 It is possible that thethe survival time after onset of candidemia among patients
95% confidence interval p
1.333e5.851 0.006*
3.160e25.702 <0.001*
6.822e164.580 <0.001*
1.372e6.510 0.006*
0.769e3.717 0.191
0.693e3.257 0.303
0.481e2.711 0.763
0.287e1.528 0.334
0.679e3.225 0.324
0.305e1.822 0.519
tal parenteral nutrition.
Candidemia in patients requiring TPN 465MIC to fluconazole is higher in isolates from patients with
breakthrough candidemia, who wound require a higher
dose of fluconazole. However, most of clinical laboratories
are not able to provide MICs of Candida species. As such,
a change in antifungal agents seems to be a reasonable
alternative for the treatment of breakthrough infections in
these situations.
All those patients who did not receive antifungal therapy
died within 2 weeks. In most cases, they died before blood
cultures yielded Candida, and this resulted in these patients
having more severe candidemia. In some reports, a better
survival rate was demonstrated in the patients treated early
with antifungal agents.27,28 Although a better survival rate
was noted in our study after controlling for APACHE II score,
this was not statistically significant because of the small
study population. Empirical use of antifungal agents before
a positive blood culture should be considered earlier in
patients requiring TPN, especially for those with higher
APACHE II scores. In our study, thrombocytopenia was also
associated with a lower survival time in patients with
candidemia requiring TPN. Some reports have also shown
that thrombocytopenia is an independent predictor of
death attributable to candidemia.21,29 Thrombocytopenia is
a marker for disseminated intravascular coagulopathy in
patients with severe infections. The retention of CVCs can
lead to thrombophlebitis with seeding of Candida into the
clots, which would affect the efficacy of antifungal agents,
prolong candidemia, and then cause disseminated intra-
vascular coagulopathy.30 When disseminated intravascular
coagulopathy develops, patients would be expected to
demonstrate a lower survival time.
A better outcome for patients requiring TPN with fun-
gemia because of C parapsilosis had been noted.31 Some
patients survived in spite of the fact that their main
treatment was only removal of the catheter. However, this
phenomenon was not observed in our study. Six of nine
patients with C parapsilosis candidemia survived more than
30 days after onset of candidemia, and they all received
antifungal agents and their CVCs were changed after the
onset of candidemia. Of the other three patients not
surviving more than 30 days, one did not receive antifungal
agents and one did not receive a change in the CVC.
Compared with the patients with C albicans candidemia
(30-day survival rate: 17/38), a better outcome was found
in patients with C parapsilosis candidemia, but this was not
shown to be statistically different because of the small
sample size.
Our study had several limitations. First, the lack of
statistical power resulting from the small sample size may
have contributed to concealing some differences among
these patients. Second, because of the retrospective design
of this study, we could not control for all confounding
variables effecting survival. Prospective studies involving
large numbers of patients are required before any firm
recommendations for changing CVCs in these patients can
be made. In conclusion, our study results indicated that
APACHE II scores are an independent prognostic factor for
30-day survival rates in patients requiring TPN after the
onset of candidemia. Thrombocytopenia, antifungal agents,
APACHE II scores, and changing of CVCs are associated with
total survival time after the onset of candidemia. Empirical
antifungal agents may be considered earlier in patientsrequiring TPNs, especially in the patients with higher
APACHE II scores. Also, changing CVCs to decrease coloni-
zation of Candida spices appears to be important for pro-
longing the survival time in these patients.References
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